Consortium of Multiple Sclerosis Centers Annual Meeting

The Long-Term Impact of Addressing Gender Norms for Men With MS

June 18, 2020

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.

Bryan Davis, PsyD, MS: Future Discussion on Masculinity Norms in MS

June 16, 2020

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.

Why Learning About Masculine Norms Can Improve MS Care

June 13, 2020

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.

Bryan Davis, PsyD, MS: Behavioral Health and CMNI in Treating MS

June 11, 2020

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.

Natalizumab Sets Itself Apart From Other MS Treatments

June 09, 2020

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MS

June 05, 2020

Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.